{'fraction_non_alphanumeric': 0.04110105580693816, 'fraction_numerical': 0.017345399698340876, 'mean_word_length': 6.037135278514588, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ANXA7 Regulates Platelet Lipid Metabolism and Ca2+ Release in Arterial Thrombosis

Supplemental Digital Content is available in the text. Rationale: Platelet activation after contact to subendothelial collagen leads to acute arterial thrombosis. ANXA7 (Annexin A7) is a phospholipid-binding protein participating in the regulation of intracellular Ca2+ and exocytosis. Objective: The present study aimed to determine the role of ANXA7 in platelet Ca2+ signaling and lipid metabolism during platelet activation in arterial thrombosis using the ANXA7 inhibitor 6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine (ABO) and gene-targeted mice lacking Anxa7 (Anxa7−/−). Methods and Results: ANXA7 is strongly expressed in platelets. Functionally, luminescence aggregometry revealed significantly abrogated aggregation and secretion of ABO-treated or Anxa7−/− platelets when compared with untreated or Anxa7+/+ platelets after activation with collagen or the GPVI (glycoprotein VI)-specific agonist collagen-related peptide. Furthermore, while both thrombus formation on collagen-coated surfaces under high arterial shear rates in ABO-treated or Anxa7-deficient whole blood, and thrombotic vascular occlusion after FeCl3-induced injury in vivo in Anxa7−/− bone marrow chimeric mice were significantly diminished, no prolongation of bleeding time was observed in ABO-treated or Anxa7−/− mice. Fura-2-AM spectrofluorimetry unraveled a blunted [Ca2+]i increase in ABO-treated or Anxa7−/− platelets after GPVI stimulation. Due to an abolished phospholipase Cγ2 phosphorylation, Anxa7−/− platelets displayed abrogated intracellular Ca2+ mobilization following collagen-related peptide-dependent platelet activation. Quantitative lipidomics analysis further revealed that ANXA7 critically affects platelet oxylipin metabolism following GPVI-dependent platelet activation. Anxa7−/− platelets showed a significantly reduced generation of several bioactive metabolites, particularly thromboxane A2 and 12(S)-hydroxy-eicosatetraenoic acid. Finally, defective phospholipase Cγ2 phosphorylation and blunted [Ca2+]i increase in Anxa7−/− platelets could be rescued by exogenous addition of 12(S)-hydroxy-eicosatetraenoic acid, indicating that ANXA7 is a critical regulator of the platelet 12-lipoxygenase in GPVI-dependent platelet Ca2+ signaling during arterial thrombosis. Conclusions: The present study unravels ANXA7 as a regulator of oxylipin metabolism and Ca2+-dependent platelet activation downstream of GPVI. ANXA7 plays an important role in platelet signaling during arterial thrombosis and thus may reflect a promising target for novel antiplatelet strategies.